Does Cyclobenzaprine have Aspirin in it?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
Does Cyclobenzaprine have Aspirin in it?
No, Cyclobenzaprine does not contain Aspirin. These two are different medications which are used for different therapeutic purposes.
Cyclobenzaprine is a prescription muscle relaxant, which can be used to control muscle spasms which are often triggered suddenly and uncontrollably. Aspirin, on the other hand, is an over-the-counter non-steroidal anti-inflammatory drug (NSAID).
Both of these meds work differently and have entirely different side effects profiles. You can take Aspirin whenever you need it but don’t take Cyclobenzaprine if not prescribed by your healthcare provider.
Why is Cyclobenzaprine prescribed and how does it affect your body?
Cyclobenzaprine is prescribed to control involuntary muscle spasms and the pain associated with them. The treatment of Cyclobenzaprine should not exceed a few weeks because this medication can affect your brain(1).
Cyclobenzaprine basically controls the movement of the skeletal muscle, without affecting the muscle directly. It does so by affecting the parts of the brain which control muscle contraction.
This is the main reason why such muscle relaxants should not be used for a long period of time. Cyclobenzaprine is associated with some side effects, like every other medication. However, you may not find this medication problematic as far as you continue using it properly.
Common side effects
- Nausea
- Vomiting
- Dry mouth
- Constipation
- Bloating
- Extreme fatigue
- Acid reflux
- Weakness
Serious and rare side effects
- An allergic reaction
- Swelling in different parts of the body
- Difficulty in breathing
- Unsteadiness
- Severe dizziness
- Difficulty in urination
- Severe depression
- Tinnitus
- Nightmares
- Pale colouration of skin and eyes
Make sure you report to your healthcare provider if you start experiencing any of the unusual or rare side effects of Cyclobenzaprine. Not every medication works well for everyone.
It’s best to discuss your side effects with your doctor and to determine whether or not it’s safe for you to continue using this medication.
Why is Aspirin used and how does it affect your body?
Aspirin is an OTC Non-steroidal anti-inflammatory drug which can be used for the management of pain, fever, and inflammation. Aspirin can also be used as a blood thinner in people who have coronary artery disease or those who are at high risk of cardiac problems(2).
Aspirin produces these effects by inhibiting the synthesis of Prostaglandins, which are important mediators of pain and inflammation. However, Prostaglandins also make up the protective lining around your stomach.
This Prostaglandin inhibition is the main reason why Aspirin causes gastrointestinal side effects.
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Acid reflux
- Flatulence
Rare and serious side effects
- An allergic reaction or hypersensitivity
- Arrhythmia or abnormal heartbeat
- Irregular breathing
- Tremors
- Bloody vomiting
- Loss of hearing
- Black or tarry stools – indicating gastrointestinal bleeding
- Ulceration
Make sure you reach out to your healthcare provider if you’re experiencing any of the rare or serious side effects of Aspirin. If you feel extreme stomach pain or find your stools to be black in colour, stop the use of Aspirin right away and talk to your doctor.
Can Cyclobenzaprine be taken with Aspirin?
Cyclobenzaprine can be taken with low-dose Aspirin, as low doses of Aspirin do not necessarily interact with Cyclobenzaprine. However, high doses can cause side effects. Cyclobenzaprine can also be taken with some other NSAIDs, like Diclofenac.
However, it’s best to discuss combining these medications with your doctor before you actually do it. People are different and can respond differently to medications. Some people may not do well on this combination because of some underlying factors. So, always discuss such things with your provider.
Was this helpful?
References
1.-
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2895, Cyclobenzaprine; [cited 2023 Mar. 03]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Cyclobenzaprine
2.-
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2244, Aspirin; [cited 2023 Mar. 03]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin
